China Resources Medical (SEHK:1515) Stock Price Flat As Earnings Cushion Thins

Simply Wall St · 2d ago

China Resources Medical Holdings stock closed at HK$2.57 today, leaving the share price almost flat over the past month while the real story sat in the income statement. The headline is margin pressure. Net profit margin on the trailing 12 months is 4.6%, lower than the 5.0% level a year earlier, and earnings over the past year moved in the wrong direction despite five year growth.

So the short term price drift masks a tougher question for you: How much weight should investors give to a P/E of 6.8x and a large gap to the estimated fair value when margins are getting squeezed?

Love the low P/E on China Resources Medical Holdings but concerned about the margin squeeze and earnings pressure? Take a look at our hand picked 292 resilient stocks with low risk scores as a benchmark for stocks combining resilience with steadier profitability.

H1 2026 Earnings Summary

Revenue (H1 2026 vs H1 2025): ¥4,478.824m vs ¥4,524.803m (slight decline in the latest half)
Net Income Excluding Extra Items (H1 2026 vs H1 2025): ¥264.902m vs ¥339.521m (decline in earnings)
Basic EPS (Earnings Per Share) (H1 2026 vs H1 2025): ¥0.21 vs ¥0.268546 (earnings per share declined)
Trailing 12 Month Net Profit Margin (latest vs prior year): 4.6% vs 5.0% (margin pressure with lower profitability)

Prefer clean charts instead of another page of earnings tables for China Resources Medical Holdings? See the full visual picture of its profitability trend in our company report for China Resources Medical Holdings.

SEHK:1515 Trailing 12-Month Revenue & Expenses Breakdown as at Aug 2026

China Resources Medical and the cautious bull story

For investors leaning positive on China Resources Medical, the latest half-year numbers make the case more about resilience than growth. Revenue of ¥4,478.824m is close to the prior ¥4,524.803m, which broadly supports the view that hospital demand is relatively steady. Earnings pressure is evident, with net income excluding extra items at ¥264.902m versus ¥339.521m and basic EPS at ¥0.21 versus ¥0.268546. That softens the defensive pitch but does not overturn it, given the essential nature of hospital services.

Margin pressure keeps the bearish narrative alive

The bearish angle on China Resources Medical focuses on squeezing margins and earnings drift, and the latest figures do not push back strongly. Net income excluding extra items declined from ¥339.521m to ¥264.902m and basic EPS fell from ¥0.268546 to ¥0.21. The trailing 12 month net profit margin eased from 5.0% to 4.6%. Revenue is broadly stable, so the pressure appears to sit more on profitability than on demand. That keeps concerns about cost control and pricing power on the table.

After margin compression, steady revenue and an unstable dividend track record, it is fair to ask whether this is just the visible risk. Review our independent risk analysis for China Resources Medical Holdings which shows 1 important warning sign

Stay Ahead With Simply Wall St

If China Resources Medical Holdings is on your radar after the recent margin pressure and low P/E debate, register for free with Simply Wall St and add it to a Watchlist so you can track price against fair value and wait for a setup that fits your plan. When you do take a position, manage everything from one place with the Portfolio Command Center that filters out noise and highlights only the updates that matter for your holdings. For a longer term view, use the Community to see how other investors are thinking about the same risks and opportunities. This way you spot potential catalysts and red flags earlier and keep a step ahead of the wider market.

Seeking Alternatives Beyond China Resources Medical

Fresh stock ideas can move from quiet to breakout before most investors even notice. Use curated screeners while it matters and before momentum gets fully caught. Get in early.

Spot potential breakout quality at a discount by scanning our curated list of 273 high quality undervalued stocks that combine cash generation with balance sheets built to handle shocks.
Ride structural infrastructure momentum by reviewing 38 power grid technology and infrastructure stocks that could benefit as capital chases stronger grids and transmission technology while these stocks are still under the radar for now.
Catch real businesses behind the AI buzz by checking 75 profitable AI stocks that aren't just burning cash that already convert demand into earnings instead of relying only on story driven expectations.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com